NEWOMICS INC. — Department of Health and Human Services SBIR Phase I: NIA

Description

DESCRIPTION provided by applicant Alzheimerandapos s disease AD is a devastating neurodegenerative disease that affects more than million people including million Americans worldwide and this number is expected to reach more than million by the year Recent disappointing clinical trials of bapineuzumab and solanezumab in AD treatment further aggravate the problem There is currently no definitive biomarker for early diagnosis or therapy of AD The field is calling for transformative technologies and approaches In response to PA Newomics Inc proposes to develop integrated silicon microfluidic chips termed AD MS chips as a revolutionary platform for rapid sensitive and specific biofluids based early diagnosis of AD The core technology will be based on Newomicsandapos breakthrough silicon microfluidic chip the multinozzle emitter array chip MEA chip Randamp D award which enables liquid chromatography nanoelectrospray ionization mass spectrometry LC nanoESI MS based highly sensitive highly specific high throughput and multiplex measurements of multiclass analytes peptides proteins and metabolites at the Omics level from small volumes of samples The project is also based on our recent discovery of several proteoforms in human plasma as potential AD biomarkers through top down proteomics studies using our MEA chips In this SBIR project we will develop AD MS chips as a high throughput and multiplex multi omics platform AD MS chips will enable high throughput and multiplex measurements of andquot multiclassandquot analytes peptides proteins and metabolites from small volumes of human plasma and cerebrospinal fluid CSF samples thereby dramatically accelerating the discovery validation and clinical application of andquot Multiclass Biomarker Panel MBP andquot for AD diagnosis If validated in future prospective clinical studies AD MS chips will enable rapid sensitive and affordable biofluids based early diagnosis of AD PUBLIC HEALTH RELEVANCE Cutting edge technologies enable breakthroughs in biomedical research Developments of innovative silicon microfluidic chips for mass spectrometry analysis of proteins peptides and small molecules will accelerate the discovery and validation of biomarkers for Alzheimerandapos s disease thereby providing new strategies for its early diagnosis and targeted therapy